Benchmark Reiterates Speculative Buy on Orgenesis, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Kenneth Bruce reiterated a Speculative Buy rating on Orgenesis (NASDAQ:ORGS) and maintained a $6 price target.
June 14, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Kenneth Bruce reiterated a Speculative Buy rating on Orgenesis and maintained a $6 price target.
The Speculative Buy rating and maintained $6 price target by Benchmark analyst Kenneth Bruce indicates a positive outlook for Orgenesis in the short term. This news is likely to attract investors and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100